Altimmune, Inc.

NASDAQ:ALT

Biotechnology

Healthcare
$1.39 +3.09%

+$0.08 today

Market cap
$270.48M
Beta
0.23
P/E (TTM)
-3.7
EPS (TTM)
-$0.73
52W Low $2.56High $7.73

Volume 4.69M

Average 3.81M

ALT Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Altimmune, Inc.NASDAQ: ALT

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital turns negative

Q1 FY2026 change in working capital was -$1.99M, compared with $73K a year earlier. Trailing-twelve-month change in working capital was $4.69M. Over 3 fiscal years it compounded at -21.8% a year.

Context

  • Change in working capital amounted to 16468.3% of revenue in FY2025, down 5921.7 pp from a year earlier.
  • Change in working capital increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly change in working capital holds near -$1.99M or moves back toward the trailing-twelve-month quarterly average of $1.17M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.99M-155.0% QoQ
Last fiscal yearDec 2025
$6.75M+50.8% YoY
LTMMar 2026
$4.69M+272.5% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2827.4%——
1 year+50.8%——
3-year CAGR-21.8%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
6.75M USD
Year-over-year change
+50.8%

Change in Working Capital vs competitors

How ALT compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +272.5% is the 3rd highest of 9, against a peer median of +32.2%.
  • Change in working capital amounts to 13022.2% of revenue for ALT, versus a peer median of 101.3%.
ALT Competitors
Change in Working Capital for ALT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABUSArbutus Biopharma CorporationLTM Mar 2026$194M USD-3761.0%—101.3%
VIRVir Biotechnology, Inc.LTM Mar 2026$71.19M USD-394.2%—108.7%
GPCRStructure Therapeutics Inc.LTM Jun 2026$54.33M USD+475.0%——
ASMBAssembly Biosciences, Inc.LTM Mar 2026$36.78M USD+105.8%+162.3%51.7%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$34.76M USD+146.8%+80.5%50.2%
IVAInventiva S.A.FY2025€6.42M EUR+282.2%+4.0%143.1%
ALTAltimmune, Inc.LTM Mar 2026$4.69M USD+272.5%-21.8%13022.2%
BMEABiomea Fusion, Inc.LTM Mar 2026$3.84M USD-41.3%——
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$621.08K USD-214.6%——
Peer median (excluding ALT) —+32.2%+80.5%101.3%

Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(97.09M)(84.71M)(88.45M)(95.06M)(88.09M)
Depreciation & Amortization551K493K477K238K112K
Deferred Income Tax0000(681K)
Stock-Based Compensation5.52M8.1M10.64M14.39M16.08M
Change in Working Capital(251K)14.11M(8.27M)4.48M6.75M
Accounts Receivables6.53M3.3M(2.31M)1.74M2.06M
Inventory00000
Accounts Payables1.42M2.77M(2.73M)(1.86M)2.51M
Other Working Capital(8.21M)8.04M(3.23M)4.6M2.19M
Other Non-Cash Items13.03M(578K)9.79M(3.9M)(1.7M)
Operating Cash Flow(78.24M)(62.59M)(75.81M)(79.85M)(67.54M)
Capital Expenditures(12.31M)(126K)(47K)0(11K)
Acquisitions (Net)00000
Purchases of Investments(7.59M)(73.27M)(88.63M)(115.73M)(285.45M)
Sales of Investments107.43M0102.41M87.35M152.99M
Other Investing Activities(195K)0000
Investing Cash Flow87.52M(73.4M)13.73M(28.39M)(132.47M)
Debt Repayment000033.92M
Common Stock Issued65.04M56.35M86.6M9.99M173.73M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities58K434K(496K)50K(709K)
Financing Cash Flow65.1M56.78M86.11M10.04M206.84M
Effect of Forex Changes00000
Net Change in Cash74.38M(79.2M)24.03M(98.19M)6.83M
Free Cash Flow(90.55M)(62.71M)(75.86M)(79.85M)(67.55M)

Altimmune, Inc.

NASDAQ:ALT

Intrinsic Alpha fair value

Locked

Current Price

$1.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.